The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin
Staphylococcus aureus may cause relapsing infections. We previously showed that S. aureus SH1000 surviving intracellularly to bactericidal antibiotics are persisters. Here, we used 54 non-duplicate clinical isolates to assess links between persistence, resistance evolution, and intracellular surviva...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2020.587364/full |
id |
doaj-0227303c1f0b4f89b535401c6e21ed1d |
---|---|
record_format |
Article |
spelling |
doaj-0227303c1f0b4f89b535401c6e21ed1d2020-11-25T04:12:22ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2020-11-011110.3389/fmicb.2020.587364587364The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With MoxifloxacinTiep K. Nguyen0Tiep K. Nguyen1Frédéric Peyrusson2Magali Dodémont3Nhung H. Pham4Nhung H. Pham5Hoang A. Nguyen6Paul M. Tulkens7Françoise Van Bambeke8Pharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, BelgiumDepartment of Pharmaceutical Industry, Hanoi University of Pharmacy, Hanoi, VietnamPharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, BelgiumCentre National de Référence des Staphylocoques, Laboratoire Hospitalier Universitaire de Bruxelles (LHUB-ULB) Site Anderlecht, Hôpital Erasme – Cliniques Universitaires de Bruxelles, Brussels, BelgiumDepartment of Microbiology, Bach Mai Hospital, Hanoi, VietnamMicrobiology Department, Hanoi Medical University, Hanoi, VietnamThe National Center for Drug Information and Adverse Drug Reactions Monitoring, Hanoi University of Pharmacy, Hanoi, VietnamPharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, BelgiumPharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, BelgiumStaphylococcus aureus may cause relapsing infections. We previously showed that S. aureus SH1000 surviving intracellularly to bactericidal antibiotics are persisters. Here, we used 54 non-duplicate clinical isolates to assess links between persistence, resistance evolution, and intracellular survival, using moxifloxacin throughout as test bactericidal antibiotic. The relative persister fraction (RPF: percentage of inoculum surviving to 100× MIC moxifloxacin in stationary phase culture for each isolate relative to ATCC 25923) was determined to categorize isolates with low (≤10) or high (>10) RPF. Evolution to resistance (moxifloxacin MIC ≥ 0.5 mg/L) was triggered by serial passages at 0.5× MIC (with daily concentration readjustments). Intracellular moxifloxacin maximal efficacy (Emax) was determined by 24 h concentration-response experiments [pharmacodynamic model (Hill-Langmuir)] with infected THP-1 monocytes exposed to moxifloxacin (0.01 to 100× MIC) after phagocytosis. Division of intracellular survivors was followed by green fluorescence protein dilution (FACS). Most (30/36) moxifloxacin-susceptible isolates showed low RPF but all moxifloxacin-resistant (n = 18) isolates harbored high RPF. Evolution to resistance of susceptible isolates was faster for those with high vs. low RPF (with SOS response and topoisomerase-encoding genes overexpression). Intracellularly, moxifloxacin Emax was decreased (less negative) for isolates with high vs. low RPF, independently from resistance. Moxifloxacin intracellular survivors were non-dividing. The data demonstrate and quantitate persisters in clinical isolates of S. aureus, and show that this phenotype accelerates resistance evolution and is associated with intracellular survival in spite of high antibiotic concentrations. Isolates with high RPF may represent a possible cause of treatment failure not directly related to resistance in patients receiving active antibiotics.https://www.frontiersin.org/articles/10.3389/fmicb.2020.587364/fullStaphylococcus aureuspersisterintracellular infectionresistanceintracellular survivalmoxifloxacin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tiep K. Nguyen Tiep K. Nguyen Frédéric Peyrusson Magali Dodémont Nhung H. Pham Nhung H. Pham Hoang A. Nguyen Paul M. Tulkens Françoise Van Bambeke |
spellingShingle |
Tiep K. Nguyen Tiep K. Nguyen Frédéric Peyrusson Magali Dodémont Nhung H. Pham Nhung H. Pham Hoang A. Nguyen Paul M. Tulkens Françoise Van Bambeke The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin Frontiers in Microbiology Staphylococcus aureus persister intracellular infection resistance intracellular survival moxifloxacin |
author_facet |
Tiep K. Nguyen Tiep K. Nguyen Frédéric Peyrusson Magali Dodémont Nhung H. Pham Nhung H. Pham Hoang A. Nguyen Paul M. Tulkens Françoise Van Bambeke |
author_sort |
Tiep K. Nguyen |
title |
The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin |
title_short |
The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin |
title_full |
The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin |
title_fullStr |
The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin |
title_full_unstemmed |
The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin |
title_sort |
persister character of clinical isolates of staphylococcus aureus contributes to faster evolution to resistance and higher survival in thp-1 monocytes: a study with moxifloxacin |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Microbiology |
issn |
1664-302X |
publishDate |
2020-11-01 |
description |
Staphylococcus aureus may cause relapsing infections. We previously showed that S. aureus SH1000 surviving intracellularly to bactericidal antibiotics are persisters. Here, we used 54 non-duplicate clinical isolates to assess links between persistence, resistance evolution, and intracellular survival, using moxifloxacin throughout as test bactericidal antibiotic. The relative persister fraction (RPF: percentage of inoculum surviving to 100× MIC moxifloxacin in stationary phase culture for each isolate relative to ATCC 25923) was determined to categorize isolates with low (≤10) or high (>10) RPF. Evolution to resistance (moxifloxacin MIC ≥ 0.5 mg/L) was triggered by serial passages at 0.5× MIC (with daily concentration readjustments). Intracellular moxifloxacin maximal efficacy (Emax) was determined by 24 h concentration-response experiments [pharmacodynamic model (Hill-Langmuir)] with infected THP-1 monocytes exposed to moxifloxacin (0.01 to 100× MIC) after phagocytosis. Division of intracellular survivors was followed by green fluorescence protein dilution (FACS). Most (30/36) moxifloxacin-susceptible isolates showed low RPF but all moxifloxacin-resistant (n = 18) isolates harbored high RPF. Evolution to resistance of susceptible isolates was faster for those with high vs. low RPF (with SOS response and topoisomerase-encoding genes overexpression). Intracellularly, moxifloxacin Emax was decreased (less negative) for isolates with high vs. low RPF, independently from resistance. Moxifloxacin intracellular survivors were non-dividing. The data demonstrate and quantitate persisters in clinical isolates of S. aureus, and show that this phenotype accelerates resistance evolution and is associated with intracellular survival in spite of high antibiotic concentrations. Isolates with high RPF may represent a possible cause of treatment failure not directly related to resistance in patients receiving active antibiotics. |
topic |
Staphylococcus aureus persister intracellular infection resistance intracellular survival moxifloxacin |
url |
https://www.frontiersin.org/articles/10.3389/fmicb.2020.587364/full |
work_keys_str_mv |
AT tiepknguyen thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT tiepknguyen thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT fredericpeyrusson thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT magalidodemont thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT nhunghpham thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT nhunghpham thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT hoanganguyen thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT paulmtulkens thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT francoisevanbambeke thepersistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT tiepknguyen persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT tiepknguyen persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT fredericpeyrusson persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT magalidodemont persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT nhunghpham persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT nhunghpham persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT hoanganguyen persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT paulmtulkens persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin AT francoisevanbambeke persistercharacterofclinicalisolatesofstaphylococcusaureuscontributestofasterevolutiontoresistanceandhighersurvivalinthp1monocytesastudywithmoxifloxacin |
_version_ |
1724415647027298304 |